Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Sanofi Invests $425M in Flu Vaccine Manufacturing Facility | Contract Pharma

What are you searching for?

Sign in
Breaking News

Sanofi Invests $425M in Flu Vaccine Manufacturing Facility

Newly licensed U.S. manufacturing facility to increase availability of Fluzone High-Dose Quadrivalent.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

The U.S. FDA Center for Biologics Evaluation and Research (CBER) has granted approval to Sanofi Pasteur, the vaccines global business unit of Sanofi, for an additional influenza manufacturing facility located in Swiftwater, PA.
 
The newly completed $425 million investment in the facility expands production and distribution of Sanofi’s Fluzone High-Dose Quadrivalent for the upcoming 2021-2022 influenza season in the U.S. and will create up to 200 additional manufacturing jobs. Commercialization activities for the U.S. market are underway, with plans to support other countries in the future.
 
“We are experiencing fast-growing demand for our vaccine in the U.S. and globally, given the 10 years of data demonstrating protection from flu and its related complications,” said Elaine O’Hara, head of North America commercial operations, Sanofi Pasteur. “Our new facility will complement our existing capacities to produce enough high-dose vaccine for all people 65 and older in as many countries as possible this flu season and beyond, supporting the needs of healthcare providers and patients.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics